作者
Fabrizio D’Ascenzo,Emad Abu‐Assi,Sergio Raposeiras‐Roubín,José P.S. Henriques,Jorge Saucedo,José Ramón González-Juanatey,Stephen B. Wilton,Wouter J. Kikkert,Iván J. Núñez‐Gil,Albert Ariza‐Solé,Xiaoyan Song,Dimitrios Alexopoulos,Christoph Liebetrau,Tetsuma Kawaji,Claudio Moretti,Zenon Huczek,Shaoping Nie,Toshiharu Fujii,Luís Cláudio Lemos Correia,Masa‐aki Kawashiri,José Marı́a Garcı́a-Acuña,Danielle Southern,Emilio Alfonso,Belén Terol,Alberto Garay,Dongfeng Zhang,Yalei Chen,Ioanna Xanthopoulou,Neriman Osman,Helge Möllmann,Hiroki Shiomi,Francesca Giordana,Silvia Scarano,Fiorenzo Gaïta,Michał Kowara,Krzysztof J. Filipiak,Xiao Wang,Yan Yan,Jingyao Fan,Yuji Ikari,Takuya Nakahayshi,Kenji Sakata,Masakazu Yamagishi,Oliver Kalpak,Saško Kedev
摘要
Background Bleeding events after an acute coronary syndrome have a negative impact on prognosis. Available risk scores are limited by suboptimal accuracy, prediction of only in-hospital events and absence of patients treated with new antiplatelet agents in the current era of widespread use of percutaneous coronary intervention. Design The BleeMACS (Bleeding complications in a Multicenter registry of patients discharged after an Acute Coronary Syndrome) project is a multicenter investigator-initiated international retrospective registry that enrolled more than 15 000 patients discharged with a definitive diagnosis of acute coronary syndrome and treated with percutaneous revascularization. The primary end point is the incidence of major bleeding events requiring hospitalization and/or red cell transfusion concentrates within 1 year. An integer risk score for bleeding within the first year after hospital discharge will be developed from a multivariate competing-risks regression. Conclusion The BleeMACS registry collaborative will allow development and validation of a risk score for prediction of major bleeding during follow-up for patients receiving contemporary therapies for acute coronary syndrome.